An Open-Label, Multicenter Extension Study of Onartuzumab in Patients with Solid Tumors on Study Treatment Previously Enrolled in an F. Hoffmann-La Roche- AND/OR Genentech-Sponsored Study
Phase 3
- Conditions
- Solid tumor
- Registration Number
- JPRN-jRCT2080222922
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Signed E-trial Informed Consent Form.
- Enrolled and receiving either control treatment or onartuzumab-based study treatment in an eligible P-trial.
- Has not met the treatment discontinuation criteria specified in their P-trial protocol at the time of enrollment into the E-trial.
Exclusion Criteria
- Pregnancy or lactation or intention to become pregnant during the study.
- Any non-protocol anti-cancer therapy started between discontinuation from treatment in P-trial and start of enrollment in E-trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method